| 2016.09 | First patient enrolled in phase II clinical trial of TM-411 in acute myeloid leukemia or myelodysplastic syndrome in US. |
|---|---|
| 2016.06 | FDA Accepts IND to Advance TM-411 submitted as SY-1425 by Syros into Phase 2 Clinical Trial in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) |
| 2015.09 | TMRC reached a license agreement with Syros Pharmaceuticals to develop and commercialize TM-411 in North America and Europe for cancer. |
| 2015.04 | Investigator initiated Phase I study of TM-411 in the relapsed/refractory pediatric solid tumor was started at the National Cancer Center Hospital in Tokyo. |
